‘Steady decline’ in C-peptide starts six months before T1D diagnosis
The findings suggest an early window of opportunity for disease-modifying therapy, researchers say
A longitudinal study tracking people as they develop type 1 diabetes shows that C-peptide levels maintain a steady decline starting six months before clinical diagnosis.
The results suggest that interventions aimed at reducing damage to beta-cells might need to be carried out earlier than previously thought, the US authors say.
